SPAG6 and renal cell carcinoma: In myelodysplastic syndrome (MDS) and Burkitt lymphoma, SPAG6 appears to promote tumor progression by activating the PI3K/AKT/mTOR pathway [26,33], which stands in stark contrast to our findings in RCC.